Monoclonal antibodies against the interferon receptor, with neutralizing activity against type I interferon
AssigneeMedarex, Inc.
InventorsPatrick Benoit, Francois Meyer, Deborah Maguire, Ivan Plavec, Michael Gerard Tovey
Life of this patent
Estimating the term…
Abstract
The invention relates to a monoclonal antibody directed against the human interferon class I receptor (IFN-R) characterized by the following properties: it recognizes the extracellular domain of the human IFN-R, and it has a neutralizing capacity against the biological properties of the human type I-IFN. It further concerns their use for the diagnosis.
Claims16
A method of producing a monoclonal antibody comprising culturing a hybridoma that produces a monoclonal antibody that binds to an isolated polypeptide consisting of amino acid residues 1 to 229 of SEQ ID NO:
- 2, and purifying the monoclonal antibody from the culture supernatant.
A method of producing a monoclonal antibody comprising culturing a hybridoma that produces a monoclonal antibody that binds to an isolated polypeptide consisting of amino acid residues 27 to position 427 of SEQ ID NO:
- 2, and purifying the monoclonal antibody from the culture supernatant.
A method of producing a hybridoma, the method comprising contacting stimulated B-lymphocytes in vitro with an isolated polypeptide consisting of amino acid residues 1 to 229 of SEQ ID NO:
- 2, fusing the resultant B-lymphocytes with B-lymphocytes immortalized with Epstein Barr virus, and isolating hybridoma cells which produce antibodies.
A method of producing hybridoma, the method comprising contacting stimulated B-lymphocytes in vitro with an isolated polypeptide consisting of amino acid residues 27 to position 427 of SEQ ID NO:
- 2, fusing the resultant B-lymphocytes with B-lymphocytes immortalized with Epstein Barr virus, and isolating hybridoma cells which produce antibodies.
Dependencies are inferred from the claim text.